NCT05588609 2025-09-18Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined CancersMerus B.V.Phase 2 Terminated13 enrolled
NCT02122172 2025-04-25Afatinib in Advanced Refractory Urothelial CancerUniversity of ChicagoPhase 2 Terminated32 enrolled 14 charts
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT01320280 2022-07-01BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate CancerUniversitätsklinikum Hamburg-EppendorfPhase 2 Terminated29 enrolled